FOXO1 suppression–induced positive crosstalk between HER2 and MET and its effect on acquired lapatinib resistance in HER2-positive gastric cancer cells
FOXO1의 불활성에 의해 유도되는 HER2와 MET의 positive crosstalk가 HER2 과발현 위암세포의 lapatinib에 대한 획득내성에 미치는 영향
- 의과대학 협동과정 종양생물학전공
- Issue Date
- 서울대학교 대학원
- 학위논문 (박사)-- 서울대학교 대학원 의과대학 협동과정 종양생물학전공, 2017. 8. 이병란.
- Background: Lapatinib is a candidate drug for treatment of trastuzumab-resistant, HER2-positive gastric cancer (GC). Unfortunately, lapatinib resistance renders this drug ineffective. The present study investigated the implication of forkhead box protein O1 (FOXO1) signaling in the acquired lapatinib resistance in HER2-positive GC cells.
Methods: Lapatinib-resistant GC cell lines (SNU-216 LR2-8) were generated in vitro by chronic exposure of lapatinib-sensitive, HER2-positive SNU-216 cells to lapatinib. SNU-216 LR cells with FOXO1 overexpression were generated by stable transfection of a constitutively active FOXO1 mutant (FOXO1A3). HER2 and MET in SNU-216 LR cells were downregulated using RNA interference. The sensitivity of GC cells to lapatinib and/or cisplatin was determined by crystal violet assay. In addition, Western blot analysis, luciferase reporter assay and RT-PCR were performed.
Results: SNU-216 LR cells showed upregulations of HER2 and MET, but downregulation of FOXO1 compared to parental SNU-216 cells. FOXO1 overexpression in SNU-216 LR cells significantly suppressed resistance to lapatinib and/or cisplatin. In addition, FOXO1 negatively controlled HER2 and MET at the transcriptional level and was negatively controlled by these molecules at the post-transcriptional level. A positive crosstalk was shown between HER2 and MET, each of which increased resistance to lapatinib and/or cisplatin.
Conclusions: FOXO1 serves as an important linker between HER2 and MET signaling pathways through negative crosstalks, and is a key regulator of the acquired lapatinib resistance in HER2-positive GC cells. These findings provide a rationale for establishing a novel treatment strategy to overcome lapatinib resistance in a subtype of GC patients.